Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA
James Spargo | June 27, 2024 | News story | Research and Development | MimiVax, Oncology, Orphan Drug Designation, Roswell Park Comprehensive Cancer Center, immunotherapies, oncology
The US Food and Drug Administration (FDA) has granted an expanded Orphan Drug Designation (ODD) for brain cancer immunotherapy SurVaxM, originally created at Roswell Park Comprehensive Cancer Center.
SurVaxM is a synthetic cancer vaccine that stimulates the immune system to attack tumour cells that carry the survivin protein, first received as an ODD though MimiVax, a spin-off of Roswell Park, in 2017, for the treatment of adult glioblastoma. This supplemental designation will expand its potential in other forms of both paediatric and adult malignant gliomas.
The immunotherapy is currently being assessed in the phase 2b SURVIVE trial in patients with newly diagnosed glioblastoma at 11 cancer centres nationwide, with a separate pilot study of the vaccine being undertaken in children and adolescents with several forms of brain cancer.
“Receiving orphan drug designations for SurVaxM emphasises the critical demand for novel and enhanced therapeutic options for people living with malignant gliomas,” says Michael Ciesielski PhD, assistant professor of Neurosurgery at Roswell Park, and CEO of MimiVax. “We hope that this designation may help to advance SurVaxM’s application for important indications beyond adult glioblastoma, including for paediatric brain cancers.”
“Roswell Park and all of Western New York have so much reason to be proud of SurVaxM and the team behind it,” said Candace S Johnson PhD, Roswell Park president and CEO. “SurVaxM is one of the few treatment options for incurable brain cancer to reach late-stage clinical trials, and everyone who supports this work is helping to speed a highly promising cancer treatment to patients who may benefit from it.”
James Spargo
Related Content
IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer
Precision medicine oncology company IDEAYA Biosciences has announced that the first patient in the IDEAYA-sponsored …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …
Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery
Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration …
